Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
48
CHGCY Quote, Financials, Valuation and Earnings
Last price:
$21.34
Seasonality move
:
5.82%
Day range:
$20.38 - $22.04
52-week range:
$14.52 - $26.00
Dividend yield:
1.28%
P/E ratio:
27.29x
P/S ratio:
9.28x
P/B ratio:
5.57x
Volume:
145K
Avg. volume:
114.3K
1-year change:
13.39%
Market cap:
$70.2B
Revenue:
$7.9B
EPS (TTM):
$0.78
Analysts' Opinion
-
Consensus RatingChugai Pharmaceutical has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Chugai Pharmaceutical has an estimated downside of -- from its current price of $21.34.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $21.34.
Fair Value
-
According to the consensus of 0 analysts, Chugai Pharmaceutical has -- downside to fair value with a price target of -- per share.
CHGCY vs. S&P 500
-
Over the past 5 trading days, Chugai Pharmaceutical has overperformed the S&P 500 by 1.41% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Chugai Pharmaceutical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Chugai Pharmaceutical has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Chugai Pharmaceutical reported revenues of $2.1B.
Earnings Growth
-
Chugai Pharmaceutical has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Chugai Pharmaceutical reported earnings per share of $0.22.
Enterprise value:
64.3B
EV / Invested capital:
5.10x
Price / LTM sales:
9.28x
EV / EBIT:
17.87x
EV / Revenue:
8.46x
PEG ratio (5yr expected):
4.51x
EV / Free cash flow:
26.47x
Price / Operating cash flow:
29.05x
Enterprise value / EBITDA:
17.87x
Gross Profit (TTM):
$5.4B
Return On Assets:
19.59%
Net Income Margin (TTM):
33.85%
Return On Equity:
22.92%
Return On Invested Capital:
22.92%
Operating Margin:
50.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $9.4B | $9.2B | $7.6B | $1.8B | $2.1B | |
| Gross Profit | $6.3B | $5.3B | $5.4B | $1.2B | $1.6B | |
| Operating Income | $4.3B | $3.4B | $3.6B | $738.6M | $1.1B | |
| EBITDA | $4.3B | $3.4B | $3.6B | $744.1M | $1.1B | |
| Diluted EPS | $0.93 | $0.74 | $0.78 | $0.16 | $0.22 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7B | $8.2B | $8.2B | $8.4B | -- | |
| Total Assets | $10.8B | $12.1B | $11.8B | $12.2B | -- | |
| Current Liabilities | $1.7B | $2.2B | $2.6B | $1.8B | -- | |
| Total Liabilities | $2B | $2.3B | $2.7B | $1.9B | -- | |
| Total Equity | $8.8B | $9.7B | $9.1B | $10.3B | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.8B | $1.9B | $2.9B | $123.9M | $886.9M | |
| Cash From Investing | -$1.1B | -$519.1M | -$1.4B | $30.2M | -$307.9M | |
| Cash From Financing | -$1.1B | -$1B | -$980M | -$441.1M | -$490M | |
| Free Cash Flow | $2.3B | $1.4B | $2.4B | $76.1M | $750M | |
CHGCY
Sector
Market Cap
$70.2B
$44.6M
Price % of 52-Week High
82.08%
45.71%
Dividend Yield
1.28%
0%
Shareholder Yield
1.13%
-0.68%
1-Year Price Total Return
13.39%
-29.09%
Beta (5-Year)
0.575
0.772
Dividend yield:
1.28%
Annualized payout:
$0.27
Payout ratio:
35.92%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$21.84
200-day SMA
Buy
Level
$20.29
Bollinger Bands (100)
Sell
Level
21.71 - 24.33
Chaikin Money Flow
Buy
Level
7M
20-day SMA
Sell
Level
$21.85
Relative Strength Index (RSI14)
Sell
Level
42.46
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-68.1063
50-day SMA
Sell
Level
$22.70
MACD (12, 26)
Sell
Level
-0.23
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Sell
Level
-3.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (2.1575)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-6.1601)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.
Stock Forecast FAQ
In the current month, CHGCY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CHGCY average analyst price target in the past 3 months is --.
-
Where Will Chugai Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Chugai Pharmaceutical share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Chugai Pharmaceutical?
Analysts are divided on their view about Chugai Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Chugai Pharmaceutical is a Sell and believe this share price will rise from its current level to --.
-
What Is Chugai Pharmaceutical's Price Target?
The price target for Chugai Pharmaceutical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CHGCY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Chugai Pharmaceutical is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CHGCY?
You can purchase shares of Chugai Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Chugai Pharmaceutical shares.
-
What Is The Chugai Pharmaceutical Share Price Today?
Chugai Pharmaceutical was last trading at $21.34 per share. This represents the most recent stock quote for Chugai Pharmaceutical. Yesterday, Chugai Pharmaceutical closed at $21.34 per share.
-
How To Buy Chugai Pharmaceutical Stock Online?
In order to purchase Chugai Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
